The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.
Identifieur interne : 000096 ( PubMed/Curation ); précédent : 000095; suivant : 000097The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.
Auteurs : Simon E. Hufton [Royaume-Uni] ; Paul Risley [Royaume-Uni] ; Christina R. Ball [Royaume-Uni] ; Diane Major [Royaume-Uni] ; Othmar G. Engelhardt [Royaume-Uni] ; Stephen Poole [Royaume-Uni]Source :
- PloS one [ 1932-6203 ] ; 2014.
Descripteurs français
- KwdFr :
- Affinité des anticorps (immunologie), Alignement de séquences, Animaux, Anticorps antiviraux (immunologie), Anticorps neutralisants (immunologie), Anticorps à domaine unique (), Anticorps à domaine unique (immunologie), Antigènes viraux (immunologie), Camélidés du Nouveau Monde, Données de séquences moléculaires, Glycoprotéine hémagglutinine du virus influenza (immunologie), Grippe humaine (immunologie), Humains, Mâle, Réactions croisées (immunologie), Spécificité des anticorps (immunologie), Séquence d'acides aminés, Techniques d'exposition à la surface cellulaire, Tests de neutralisation, Virus de la grippe A (), Virus de la grippe A (immunologie), Épitopes (immunologie).
- MESH :
- immunologie : Affinité des anticorps, Anticorps antiviraux, Anticorps neutralisants, Anticorps à domaine unique, Antigènes viraux, Glycoprotéine hémagglutinine du virus influenza, Grippe humaine, Réactions croisées, Spécificité des anticorps, Virus de la grippe A, Épitopes.
- Alignement de séquences, Animaux, Anticorps à domaine unique, Camélidés du Nouveau Monde, Données de séquences moléculaires, Humains, Mâle, Séquence d'acides aminés, Techniques d'exposition à la surface cellulaire, Tests de neutralisation, Virus de la grippe A.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Antibodies, Neutralizing (immunology), Antibodies, Viral (immunology), Antibody Affinity (immunology), Antibody Specificity (immunology), Antigens, Viral (immunology), Camelids, New World, Cell Surface Display Techniques, Cross Reactions (immunology), Epitopes (immunology), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Humans, Influenza A virus (classification), Influenza A virus (immunology), Influenza, Human (immunology), Male, Molecular Sequence Data, Neutralization Tests, Sequence Alignment, Single-Domain Antibodies (chemistry), Single-Domain Antibodies (immunology).
- MESH :
- chemical , chemistry : Single-Domain Antibodies.
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral, Antigens, Viral, Epitopes, Hemagglutinin Glycoproteins, Influenza Virus, Single-Domain Antibodies.
- classification : Influenza A virus.
- immunology : Antibody Affinity, Antibody Specificity, Cross Reactions, Influenza A virus, Influenza, Human.
- Amino Acid Sequence, Animals, Camelids, New World, Cell Surface Display Techniques, Humans, Male, Molecular Sequence Data, Neutralization Tests, Sequence Alignment.
Abstract
The response to the 2009 A(H1N1) influenza pandemic has highlighted the need for additional strategies for intervention which preclude the prior availability of the influenza strain. Here, 18 single domain VHH antibodies against the 2009 A(H1N1) hemagglutinin (HA) have been isolated from a immune alpaca phage displayed library. These antibodies have been grouped as having either (i) non-neutralising, (ii) H1N1 restricted neutralising or (iii) broad cross-subtype neutralising activity. The ability to neutralise different viral subtypes, including highly pathogenic avian influenza (H5N1), correlated with the absence of hemagglutination inhibition activity, loss of binding to HA at acid pH and the absence of binding to the head domain containing the receptor binding site. This data supports their binding to epitopes in the HA stem region and a mechanism of action other than blocking viral attachment to cell surface receptors. After conversion of cross-neutralising antibodies R1a-B6 and R1a-A5 into a bivalent format, no significant enhancement in neutralisation activity was seen against A(H1N1) and A(H5N1) viruses. However, bivalent R1a-B6 showed an 18 fold enhancement in potency against A(H9N2) virus and, surprisingly, gained the ability to neutralise an A(H2N2) virus. This demonstrates that cross-neutralising antibodies, which make lower affinity interactions with the membrane proximal stem region of more divergent HA sub-types, can be optimised by bivalency so increasing their breadth of anti-viral activity. The broad neutralising activity and favourable characteristics, such as high stability, simple engineering into bivalent molecules and low cost production make these single domain antibodies attractive candidates for diagnostics and immunotherapy of pandemic influenza.
DOI: 10.1371/journal.pone.0103294
PubMed: 25084445
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000096
Links to Exploration step
pubmed:25084445Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.</title><author><name sortKey="Hufton, Simon E" sort="Hufton, Simon E" uniqKey="Hufton S" first="Simon E" last="Hufton">Simon E. Hufton</name><affiliation wicri:level="1"><nlm:affiliation>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Risley, Paul" sort="Risley, Paul" uniqKey="Risley P" first="Paul" last="Risley">Paul Risley</name><affiliation wicri:level="1"><nlm:affiliation>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Ball, Christina R" sort="Ball, Christina R" uniqKey="Ball C" first="Christina R" last="Ball">Christina R. Ball</name><affiliation wicri:level="1"><nlm:affiliation>Technology Development and Infrastructure, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Technology Development and Infrastructure, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Major, Diane" sort="Major, Diane" uniqKey="Major D" first="Diane" last="Major">Diane Major</name><affiliation wicri:level="1"><nlm:affiliation>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Engelhardt, Othmar G" sort="Engelhardt, Othmar G" uniqKey="Engelhardt O" first="Othmar G" last="Engelhardt">Othmar G. Engelhardt</name><affiliation wicri:level="1"><nlm:affiliation>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Poole, Stephen" sort="Poole, Stephen" uniqKey="Poole S" first="Stephen" last="Poole">Stephen Poole</name><affiliation wicri:level="1"><nlm:affiliation>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25084445</idno><idno type="pmid">25084445</idno><idno type="doi">10.1371/journal.pone.0103294</idno><idno type="wicri:Area/PubMed/Corpus">000096</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000096</idno><idno type="wicri:Area/PubMed/Curation">000096</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000096</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.</title><author><name sortKey="Hufton, Simon E" sort="Hufton, Simon E" uniqKey="Hufton S" first="Simon E" last="Hufton">Simon E. Hufton</name><affiliation wicri:level="1"><nlm:affiliation>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Risley, Paul" sort="Risley, Paul" uniqKey="Risley P" first="Paul" last="Risley">Paul Risley</name><affiliation wicri:level="1"><nlm:affiliation>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Ball, Christina R" sort="Ball, Christina R" uniqKey="Ball C" first="Christina R" last="Ball">Christina R. Ball</name><affiliation wicri:level="1"><nlm:affiliation>Technology Development and Infrastructure, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Technology Development and Infrastructure, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Major, Diane" sort="Major, Diane" uniqKey="Major D" first="Diane" last="Major">Diane Major</name><affiliation wicri:level="1"><nlm:affiliation>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Engelhardt, Othmar G" sort="Engelhardt, Othmar G" uniqKey="Engelhardt O" first="Othmar G" last="Engelhardt">Othmar G. Engelhardt</name><affiliation wicri:level="1"><nlm:affiliation>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Poole, Stephen" sort="Poole, Stephen" uniqKey="Poole S" first="Stephen" last="Poole">Stephen Poole</name><affiliation wicri:level="1"><nlm:affiliation>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire</wicri:regionArea></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Antibodies, Neutralizing (immunology)</term><term>Antibodies, Viral (immunology)</term><term>Antibody Affinity (immunology)</term><term>Antibody Specificity (immunology)</term><term>Antigens, Viral (immunology)</term><term>Camelids, New World</term><term>Cell Surface Display Techniques</term><term>Cross Reactions (immunology)</term><term>Epitopes (immunology)</term><term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term><term>Humans</term><term>Influenza A virus (classification)</term><term>Influenza A virus (immunology)</term><term>Influenza, Human (immunology)</term><term>Male</term><term>Molecular Sequence Data</term><term>Neutralization Tests</term><term>Sequence Alignment</term><term>Single-Domain Antibodies (chemistry)</term><term>Single-Domain Antibodies (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Affinité des anticorps (immunologie)</term><term>Alignement de séquences</term><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps neutralisants (immunologie)</term><term>Anticorps à domaine unique ()</term><term>Anticorps à domaine unique (immunologie)</term><term>Antigènes viraux (immunologie)</term><term>Camélidés du Nouveau Monde</term><term>Données de séquences moléculaires</term><term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term><term>Grippe humaine (immunologie)</term><term>Humains</term><term>Mâle</term><term>Réactions croisées (immunologie)</term><term>Spécificité des anticorps (immunologie)</term><term>Séquence d'acides aminés</term><term>Techniques d'exposition à la surface cellulaire</term><term>Tests de neutralisation</term><term>Virus de la grippe A ()</term><term>Virus de la grippe A (immunologie)</term><term>Épitopes (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Single-Domain Antibodies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Antigens, Viral</term><term>Epitopes</term><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Single-Domain Antibodies</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Affinité des anticorps</term><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term><term>Anticorps à domaine unique</term><term>Antigènes viraux</term><term>Glycoprotéine hémagglutinine du virus influenza</term><term>Grippe humaine</term><term>Réactions croisées</term><term>Spécificité des anticorps</term><term>Virus de la grippe A</term><term>Épitopes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Affinity</term><term>Antibody Specificity</term><term>Cross Reactions</term><term>Influenza A virus</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Camelids, New World</term><term>Cell Surface Display Techniques</term><term>Humans</term><term>Male</term><term>Molecular Sequence Data</term><term>Neutralization Tests</term><term>Sequence Alignment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Alignement de séquences</term><term>Animaux</term><term>Anticorps à domaine unique</term><term>Camélidés du Nouveau Monde</term><term>Données de séquences moléculaires</term><term>Humains</term><term>Mâle</term><term>Séquence d'acides aminés</term><term>Techniques d'exposition à la surface cellulaire</term><term>Tests de neutralisation</term><term>Virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The response to the 2009 A(H1N1) influenza pandemic has highlighted the need for additional strategies for intervention which preclude the prior availability of the influenza strain. Here, 18 single domain VHH antibodies against the 2009 A(H1N1) hemagglutinin (HA) have been isolated from a immune alpaca phage displayed library. These antibodies have been grouped as having either (i) non-neutralising, (ii) H1N1 restricted neutralising or (iii) broad cross-subtype neutralising activity. The ability to neutralise different viral subtypes, including highly pathogenic avian influenza (H5N1), correlated with the absence of hemagglutination inhibition activity, loss of binding to HA at acid pH and the absence of binding to the head domain containing the receptor binding site. This data supports their binding to epitopes in the HA stem region and a mechanism of action other than blocking viral attachment to cell surface receptors. After conversion of cross-neutralising antibodies R1a-B6 and R1a-A5 into a bivalent format, no significant enhancement in neutralisation activity was seen against A(H1N1) and A(H5N1) viruses. However, bivalent R1a-B6 showed an 18 fold enhancement in potency against A(H9N2) virus and, surprisingly, gained the ability to neutralise an A(H2N2) virus. This demonstrates that cross-neutralising antibodies, which make lower affinity interactions with the membrane proximal stem region of more divergent HA sub-types, can be optimised by bivalency so increasing their breadth of anti-viral activity. The broad neutralising activity and favourable characteristics, such as high stability, simple engineering into bivalent molecules and low cost production make these single domain antibodies attractive candidates for diagnostics and immunotherapy of pandemic influenza. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25084445</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>8</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.</ArticleTitle><Pagination><MedlinePgn>e103294</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0103294</ELocationID><Abstract><AbstractText>The response to the 2009 A(H1N1) influenza pandemic has highlighted the need for additional strategies for intervention which preclude the prior availability of the influenza strain. Here, 18 single domain VHH antibodies against the 2009 A(H1N1) hemagglutinin (HA) have been isolated from a immune alpaca phage displayed library. These antibodies have been grouped as having either (i) non-neutralising, (ii) H1N1 restricted neutralising or (iii) broad cross-subtype neutralising activity. The ability to neutralise different viral subtypes, including highly pathogenic avian influenza (H5N1), correlated with the absence of hemagglutination inhibition activity, loss of binding to HA at acid pH and the absence of binding to the head domain containing the receptor binding site. This data supports their binding to epitopes in the HA stem region and a mechanism of action other than blocking viral attachment to cell surface receptors. After conversion of cross-neutralising antibodies R1a-B6 and R1a-A5 into a bivalent format, no significant enhancement in neutralisation activity was seen against A(H1N1) and A(H5N1) viruses. However, bivalent R1a-B6 showed an 18 fold enhancement in potency against A(H9N2) virus and, surprisingly, gained the ability to neutralise an A(H2N2) virus. This demonstrates that cross-neutralising antibodies, which make lower affinity interactions with the membrane proximal stem region of more divergent HA sub-types, can be optimised by bivalency so increasing their breadth of anti-viral activity. The broad neutralising activity and favourable characteristics, such as high stability, simple engineering into bivalent molecules and low cost production make these single domain antibodies attractive candidates for diagnostics and immunotherapy of pandemic influenza. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hufton</LastName><ForeName>Simon E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risley</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Christina R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Technology Development and Infrastructure, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Major</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Othmar G</ForeName><Initials>OG</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poole</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061905">Single-Domain Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000915" MajorTopicYN="N">Antibody Affinity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002161" MajorTopicYN="N">Camelids, New World</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061505" MajorTopicYN="N">Cell Surface Display Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061905" MajorTopicYN="N">Single-Domain Antibodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25084445</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0103294</ArticleId><ArticleId IdType="pii">PONE-D-14-18443</ArticleId><ArticleId IdType="pmc">PMC4118869</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2011;6(4):e17665</Citation><ArticleIdList><ArticleId IdType="pubmed">21483777</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2009 Apr 21;6(4):e1000049</Citation><ArticleIdList><ArticleId IdType="pubmed">19381279</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2006 Oct 17;145(8):599-609</Citation><ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 1988 Feb;26(2):333-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3343328</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull Hist Med. 2002 Spring;76(1):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11875246</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2009 May 8;388(3):541-58</Citation><ArticleIdList><ArticleId IdType="pubmed">19285987</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):850-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21798894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2010 May;120(5):1663-73</Citation><ArticleIdList><ArticleId IdType="pubmed">20389023</ArticleId></ArticleIdList></Reference><Reference><Citation>Proteins. 1995 Sep;23(1):115-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8539243</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008;3(12):e3942</Citation><ArticleIdList><ArticleId IdType="pubmed">19079604</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Apr 15;203(8):1063-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21450996</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology. 2009 Jan;49(1):39-49</Citation><ArticleIdList><ArticleId IdType="pubmed">19085971</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2010 Dec;88(3):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20849879</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23027945</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Oct;82(19):9753-64</Citation><ArticleIdList><ArticleId IdType="pubmed">18632867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Immunol. 2000 Aug;37(10):579-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11163394</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2004 Aug 1;325(2):287-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15246268</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2011 Apr 1;186(7):4331-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21357542</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Biotechnol. 2012;12:77</Citation><ArticleIdList><ArticleId IdType="pubmed">23110350</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Microbiol Biotechnol. 2007 Nov;77(1):13-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17704915</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Jun 25;274(26):18218-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10373423</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Sep 14;337(6100):1343-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22878502</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2003 Jan 10;325(2):337-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12488099</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Jul 12;28(31):4895-902</Citation><ArticleIdList><ArticleId IdType="pubmed">20553769</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1993 May;67(5):2552-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7682624</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2008 Nov;80(2):168-77</Citation><ArticleIdList><ArticleId IdType="pubmed">18598723</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 2006 Feb 1;349(1):136-47</Citation><ArticleIdList><ArticleId IdType="pubmed">16337141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2009 Jun;10(6):573-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19448659</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 May 8;24(19):4130-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16616802</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Sci. 2002 Mar;11(3):500-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11847273</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Jun 22;336(6088):1534-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22723413</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2006 Jun;54(6):1856-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16736523</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2009 Jan 30;284(5):3273-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19010777</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Environ Microbiol. 2005 Jan;71(1):442-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15640220</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(6):226-49</Citation><ArticleIdList><ArticleId IdType="pubmed">22728439</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):178-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19026455</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1997 Oct;78 ( Pt 10):2431-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9349461</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Apr 10;324(5924):246-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19251591</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2010 Feb;2(2):532-46</Citation><ArticleIdList><ArticleId IdType="pubmed">21994647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S54-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18820578</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19004788</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Oct 4;357(14):1450-1</Citation><ArticleIdList><ArticleId IdType="pubmed">17914053</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Immunol. 2009;28(1):69-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19241254</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Feb 23;354(8):785-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16495389</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2013 Jul 17;14(1):93-103</Citation><ArticleIdList><ArticleId IdType="pubmed">23870317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Sep 27;489(7417):526-32</Citation><ArticleIdList><ArticleId IdType="pubmed">22982990</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2005 Mar;23(3):344-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15723048</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Biochem. 2000;69:531-69</Citation><ArticleIdList><ArticleId IdType="pubmed">10966468</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Dec 30;27 Suppl 6:G33-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20006138</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1988 Jun 2;333(6172):426-31</Citation><ArticleIdList><ArticleId IdType="pubmed">3374584</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Apr 21;281(16):10706-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16481314</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Nov 11;26(48):6068-76</Citation><ArticleIdList><ArticleId IdType="pubmed">19007587</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Struct Mol Biol. 2009 Mar;16(3):265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19234466</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(5):2814-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15709000</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2013 Jan;19(1):12-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23295998</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Apr 15;52(8):1003-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21460314</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Jan 9;279(2):1256-61</Citation><ArticleIdList><ArticleId IdType="pubmed">14527957</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 Feb 15;445(7129):732-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17301785</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91</Citation><ArticleIdList><ArticleId IdType="pubmed">18413603</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2009;6:224</Citation><ArticleIdList><ArticleId IdType="pubmed">20025741</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2007 Dec;25(12):1421-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18066039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1993 Jun 3;363(6428):446-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8502296</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1997 Feb 1;158(3):1222-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9013963</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 1983 Apr;11 Pt 2:145-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6873453</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Sep 7;443(7107):45-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16915235</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(5):e36438</Citation><ArticleIdList><ArticleId IdType="pubmed">22590544</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2011 Jan 17;208(1):181-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21220454</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2010 Dec;16(12):1389-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21135852</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12205-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8618870</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1997 Sep 15;414(3):521-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9323027</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Disord Drug Targets. 2007 Dec;7(4):318-28</Citation><ArticleIdList><ArticleId IdType="pubmed">18220963</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Dec;82(24):12069-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18842738</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Jun 21;486(7403):420-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22722205</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2000 Mar 1;19(5):921-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10698934</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1982 Mar 11;296(5853):115-21</Citation><ArticleIdList><ArticleId IdType="pubmed">6174870</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):843-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21737702</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 2007 Jul 31;324(1-2):13-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17568607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000096 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000096 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25084445
|texte= The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25084445" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |